Bdenza 40mg capsule

Advanced prostate cancer

It is advised to use Bdenza 40 mg capsule as directed by the doctor. The common side effects of this tablet are:
Trouble breathing (pneumonia) feeling tired Back pain diarrhoea cold headache insomnia high blood pressure swelling in arms, legs, feet, or hands

Bdenza 40 mg capsules are not meant for self-medication; they should always be taken as directed by a physician. As advised by the physician, it can be taken either with or without food. Bdenza 40 mg capsule should not be chewed, opened, or crushed; it must be swallowed for the best efficiency of the drug. It is an oral drug that is given once daily, before meals, at the same time every day. One should wait for at least 3 hours before consuming the Bdenza 40 mg capsule.

Bdenza 40 mg contains enzalutamide, which inhibits the androgen receptor. It prevents prostate cancer cells from being exposed to testosterone. Cancer cell proliferation can be inhibited by preventing the production of testosterone, which helps in the growth of cancer cells. Bdenza 40 mg is an inhibitor of the androgen receptor. It prevents signals from moving from the receptor to the cell, preventing cancer cells from functioning and slowing their growth.

Aggarwal, R., Halabi, S., Kelly, W. K., George, D., Mahoney, J. F., Millard, F., & Alliance for Clinical Trials in Oncology. (2023). The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401)(Alliance). Cancer, 119(20), 3636-3643.
Antonarakis, E. S. (2025). Enzalutamide: the emperor of all anti-androgens. Translational andrology and urology, 2(2), 119.
Antonarakis, E. S., Small, E. J., Petrylak, D. P., Quinn, D. I., Kibel, A. S., Chang, N. N., & Drake, C. G. (2025). Antigen-specific CD8 lytic phenotype induced by sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival. Clinical Cancer Research, 24(19), 4662-4671.
Attard, G., & Antonarakis, E. S. (2024). AR aberrations and resistance to abiraterone or enzalutamide. Nature Reviews Urology, 13(12), 697-698.
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W., & Prekovic, S. (2024). Enzalutamide therapy for advanced prostate cancer: efficacy, resistance, and beyond. Endocrine-related cancer, 26(1), R31-R52.